SUMMARY OF INVENTION
Mesothelin (MSLN) is a cell-surface antigen which is highly expressed in solid tumors including mesothelioma, lung, pancreas, colorectal, breast, and ovarian. Investigators have developed a CAR T-cell technology targeting MSLN-expressing tumors. MSK clinical trials testing the MSLN CAR in mesothelioma (regional delivery) and triple-negative breast cancer (systemic delivery) have shown tumor-targeting ability with remarkable safety and evidence of efficacy, creating opportunities for cell therapies.
The non-T-cell (including NK, B cell, and macrophage) field of use for mesothelin CAR is available for license.
- Ability to target multiple solid tumor and AML (acute myeloid leukemia) indications
- Mesothelin CAR is currently being tested in multiple clinical trials
- Supporting data using novel costimulatory domains and / or cell-intrinsic checkpoint inhibition (PD1 dominant negative receptor) within mesothelin CAR construct is also available
Mesothelin CAR therapy has the potential to treat multiple solid malignancies and AML, with estimated annual incidence of >400K patients and a prevalence of 2M patients within the U.S alone.
STAGE OF DEVELOPMENT
Extensive portfolio of pending applications
- A phase 1 trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab (PMID: 34266984)
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity (PMID: 25378643)
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition (PMID: 27454297)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors (PMID: 26503962)
LEAD INVESTIGATOR Prasad S. Adusumilli, MD, Vice Chair, Dept. of Surgery, Memorial Sloan Kettering